Tag
IL-6 receptor inhibition during hematopoietic stem cell transplantation fosters type I interferon responses and promotes expansion of cytolytic CD4+ T cells, including Eomes+ subsets, augmenting antitumor immunity while mitigating graft-ver
This analysis of BMT CTN 1202 reveals that rabbit ATG exposure influences survival, relapse, and immune recovery after T-replete hematopoietic cell transplantation, advocating for model-based dosing to optimize outcomes.
A phase 1 trial demonstrates the safety and promising efficacy of expanded minor histocompatibility antigen-specific donor regulatory T cells as a novel prophylactic approach to reduce graft-versus-host disease and improve survival post-all
This phase 1 trial demonstrates that expanded minor histocompatibility antigen-specific donor regulatory T cells, combined with sirolimus prophylaxis, are safe and show promise in preventing acute and chronic GVHD post-allogeneic HCT with d
In AML patients undergoing unrelated donor allo-HCT with intermediate-intensity conditioning, ATG-based GvHD prophylaxis demonstrated better overall and leukemia-free survival and reduced relapse compared to alemtuzumab, despite higher acut
A randomized pilot trial shows comparable survival and safety outcomes for anti-thymocyte globulin alone versus combined with post-transplant cyclophosphamide, supporting further phase III investigation for graft-versus-host disease prophyl
This multicenter study identifies peripheral blood stem cell use as a key risk factor for early inflammatory complications post-haploidentical HSCT in children, linking these events to refractory acute and chronic graft-versus-host disease.
Early immune profiling after allogeneic stem cell transplant was linked to survival and relapse risk. Stronger innate and adaptive immune recovery predicted better outcomes, while certain activation and checkpoint markers were associated wi
